A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...

Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that ...

Editas Medicine is a clinical-stage drugmaker developing CRISPR-based gene therapies. So far, Editas Medicine's candidate for sickle cell disease patients is performing well in clinical trials. Editas ...

Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases. Editas Medicine, Inc. has announced a strategic ...

In a new study, scientists at the Max Planck Institute for Evolutionary Anthropology in Leipzig analyzed the impact of over 2,000 clinically approved drugs on DNA repair and CRISPR genome editing ...

As CRISPR moves from lab success to real-world medicine, 2026 will test whether these revolutionary gene-editing therapies ...

A live webcast of the presentation will be available on the "Events & Presentations" page in the Investors section of the ...

Editas Medicine is a gene-editing biotech, just like CRISPR Therapeutics. Editas has a long way to go before it'll be self-sustaining, and it might not get there. It's also going to be facing down ...

Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene ...

Shares of Crispr Therapeutics CRSP and Vertex Pharmaceuticals Inc. VRTX gained ground premarket on Thursday after the companies got the world’s first regulatory authorization for a medicine based on ...